The role of immunoglobulin E and Immune inflammation: Implications in allergic rhinitis

Current Allergy and Asthma Reports

Volumn 5, Issue 3, 2005, Pages 252-258

  Poole, Jill A ^a   Rosenwasser, Lanny J ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; B LYMPHOCYTE RECEPTOR; CD23 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 4; LUMILIXIMAB; MESSENGER RNA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 23; OMALIZUMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIGEN PRESENTING CELL; BASOPHIL; BASOPHIL DEGRANULATION; BINDING AFFINITY; CELL ACTIVATION; CLINICAL TRIAL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG SAFETY; DRUG TARGETING; GENE REARRANGEMENT; HISTAMINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATION; MAST CELL; MAST CELL DEGRANULATION; NOSE SECRETION; PROTEIN BINDING; PROTEIN CROSS LINKING; PROTEIN SYNTHESIS REGULATION; REVIEW; T LYMPHOCYTE;

EID: 20044373466     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-005-0045-5     Document Type: Review

References (56)

1. Ishizaka K, Ishizaka T: Identification of gamma-E-antibodies as a carrier of reaginic activity. J Immunol 1967, 99:1187-1198.
2. Sutton BJ, Gould HJ: The human IgE network. Nature 1993, 366:421-428.
3. Garman SC, Wurzburg BA, Tarchevskaya SS, et al.: Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha. Nature 2000, 406:259-266.
4. Bloebaum RM, Dharajiya N, Grant JA: Mechanisms of IgE-mediated allergic reactions. Clin Allergy Immunol 2004, 18:65-84.
5. Geha RS, Jabara HH, Brodeur SR: The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol 2003, 3:721-732.
6. Kijimoto-Ochiai S: CD23 (the low-affinity IgE receptor) as a C-type lectin: a multidomain and multifunctional molecule. Cell Mol Life Sci 2002, 59:648-664.
7. Nissim A, Schwarzbaum S, Siraganian R, Eshhar Z: Fine specificity of the IgE interaction with the low and high affinity Fc receptor. J Immunol 1993, 150:1365-1374.
8. Presta L, Shields R, O'Connell L, et al.: The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994, 269:26368-26373.
9. Jabara HH, Ahern DJ, Vercelli D, Geha RS: Hydrocortisone and IL-4 induce IgE isotype switching in human B cells. J Immunol 1991 147:1557-1560.
10. Jabara HH, Ahern DJ, Vercelli D, Geha RS: Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001, 107:371-378.
11. Litinskiy MB, Nardelli B, Hilbert DM, et al.: DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002, 3:822-829.
12. Brodeur SR, Angelini F, Bacharier LB, et al.: C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity 2003, 18:837-848.
13. Harris MB, Chang CC, Berton MT, et al.: Transcriptional repression of STAT6-dependent interleukin-4 induced genes by BCL-6: specific regulation of epsilon transcription and immunoglobulin E switching. Mol Cell Biol 1999, 19:7264-7275.
14. Turner H, Kinet JP: Signalling through the high-affinity IgE receptor Fcepsilon RI. Nature 1999, 402:B24-B30.
15. Novak N, Kraft S, Bieber T: IgE receptors. Curr Opin Immunol 2001, 13:721-726.
16. Alber G, Miller L, Jelsema CL, et al.: Structure-function relationships in the mast cell high affinity receptor for IgE: role of the cytoplasmic domains and of the beta subunit. J Biol Chem 1991, 266:22613-22620.
17. Donnadieu E, Jouvin MH, Kinet JP: A second amplifier function for the allergy-associated Fc(epsilon)RI-beta subunit. Immunity 2000, 12:515-523.
18. Garman SC, Kinet JP, Jardetzky TS: Crystal structure of the human high-affinity IgE receptor. Cell 1998, 95:951-961.
19. MacGlashan DW, Bochner BS, Adelman DC, et al.: Serum IgE level drives basophil and mast cell IgE receptor display. Int Arch Allergy Immunol 1997, 113:45-47.
20. MacGlashan DW, Bochner BS, Adelman DC, et al.: Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438-1445.
21. Saini SS, MacGlashan DW, Sterbinsky SA, et al.: Down-regulation of human basophil IgE and Fc epsilon RI alpha surface densities and mediator release by anti-IgE-infusion is reversible in vitro and in vivo. J Immunol 1999, 162:5624-5630.
22. Prussin C, Griffith DT, Boesel KM, et al.: Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003, 112:1147-1154.
23. Borkowski TA, Jouvin MH, Lin SY, Kinet JP: Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol 2001, 167:1290-1296.
24. Hakonarson H, Carter C, Kim C, Grunstein MM: Altered expression and action of the low-affinity IgE receptor Fcepsilon RII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 1999, 104:575-584.
25. Novak N, Kraft S, Bieber T. Unraveling the mission of Fcepsilon RI on antigen-presenting cells. J Allergy Clin Immunol 2003, 111:38-44.
26. Bonnefoy JY, Plater-Zyberk C, Lecoanet-Henchoz S, et al.: A new role for CD23 in inflammation. Immunol Today 1996, 17:418-420.
27. Aubry JP, Pochon S, Graber P, et al.: CD21 is a ligand for CD23 and regulates IgE production. Nature 1992, 358:505-507.
28. Borish L, Mascali JJ, Rosenwasser LJ: IgE-dependent cytokine production by human peripheral blood mononuclear phagocytes. J Immunol 1991, 146:63-67.
29. William J, Johnson S, Mascali JJ, et al.: Regulation of low affinity IgE receptor (CD23) expression on mononuclear phagocytes in normal and asthmatic subjects. J Immunol 1992, 149:2823-2829.
30. Joseph M, Tonnel AB, Torpier G, et al.: Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients. J Clin Invest 1983, 71:221-230.
31. Tsicopoulos A, Joseph M: The role of CD23 in allergic disease. Clin Exp Allergy 2000, 30:602-605.
32. Borish L, Williams J, Johnson S, et al.: Anti-inflammatory effects of nedocromil sodium: inhibition of alveolar macrophage function. Clin Exp Allergy 1992, 22:984-990.
33. Harkins MS, Moseley PL, Iwamoto GK: Regulation of CD23 in the chronic inflammatory response in asthma: a role for interferon-gamma and beat shock protein 70 in the Th2 environment. Ann Allergy Asthma Immunol 2003, 91:567-574.
34. Lecoanet-Henchoz S, Gauchat JF, Aubry JP, et al.: CD23 regulates monocyte activation through a novel interaction with the adhesion molecules CD11b-CD18 and CD11c-CD18. Immunity 1995, 3:119-125.
35. Van der Heijden FL, Joost van Neerven RJ, van Katwijk M, et al.: Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 1993, 150:3643-3650.
36. Henchoz S, Gauchat JF, Aubry JP, et al.: Stimulation of human IgE production by a subset of anti-CD21 monoclonal anti-bodies: requirement of a co-signal to modulate epsilon transcripts. Immunology 1994, 81:285-290.
37. Campbell KA, Lees A, Finkelman FD, Conrad DH: Co-crosslinking Fc epsilon RII/CD23 and B cell surface immunoglobulin modulates B cell activation. Eur J Immunol 1992, 22:2107-2112.
38. Rosenwasser LJ, Busse WW, Lizambri RG, et al.: Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003, 112:563-570.
39. Von Bubnoff D, Geiger E, Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol 2001, 108:329-339.
40. Karagiannis SN, Warrack JK, Jennings KH, et al.: Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells. Immunology 2001, 103:319-331.
41. Lin YJ, Kanzler H, Soumelis, Gilliet M: Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001, 2:585-589.
42. Feuchtinger T, Bartz H, von Berg A, et al.: Treatment with omalizumab normalizes the number of myeloid dendritic cells during the grass pollen season. J Allergy Clin Immunol 2003, 111:428-430.
43. Presta LG, Lahr SJ, Shields RL, et al.: Humanization of an antibody directed against IgE. J Immunol 1993, 151:2623-2632.
44. Lanier BQ: Newer aspects in the treatment of pediatric and adult asthma: monoclonal anti-IgE. Ann Allergy Asthma Immunol 2003, 90(6 Suppl 3):13-15.
45. Shields RL, Whether WR, Zioncheck, et al.: Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995, 107:308-312.
46. Casale TB, Condemi J, LaForce C, et al.: Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
47. Adelroth E, Rak S, Haahtela T, et al.: Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000, 106:253-259.
48. Chervinsky P, Casale T, Townley R, et al.: Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003, 91:160-167.
49. Kuehr J, Brauburger J, Zielen S, et al.: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:274-280.
50. Noga O, Hanf G, Kunkel G: Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003, 131:46-52.
51. Kopp MV, Brauburger J, Riedinger F, et al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 110:728-735.
52. Kopp MV, Mayatepek E, Engels E, et al.: Urinary leukotriene E4 levels in children with allergic rhinitis treated with specific immunotherapy and anti-IgE (omalizumab). Pediatr Allergy Immunol 2003, 14:401-404.
53. Corren J, Diaz-Sanchez D, Saxon A, et al.: Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol 2004, 93:243-248.
54. Plewako H, Arvidsson M, Petruson K, et al.: The effect of omalizumab, on nasal allergic inflammation. J Allergy Clin Immunol 2002, 110:68-71.
55. Bez C, Schubert R, Kopp M, et al.: Effect of anti-immunoglobulin E on nasal inflammation in patients with season allergic rhinoconjunctivitis. Clin Exp Allergy 2004, 34:1079-1085.
56. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ: Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996, 98:843-845.